On Friday, Teck Resources Ltd (USA) (NYSE:TCK)’s shares declined -0.94% to $10.57.
Teck Resources Limited (TCK) will release its second quarter 2015 earnings results on Thursday, July 23, 2015 before market open.
The company will hold an investor conference call to talk about the second quarter 2015 earnings results at 11:00 a.m. Eastern time / 8:00 a.m. Pacific time on Thursday, July 23, 2015. The conference call dial-in is 416.340.2216 or toll free 866.225.0198, no pass code required. Media are invited to attend on a listen-only basis.
Teck Resources Limited explores, develops, and produces natural resources in the Americas, the Asia Pacific, Europe, and Africa. Its principal products comprise copper, counting copper concentrates and cathode copper; steelmaking coal; and refined zinc and zinc concentrates. The company also produces lead, molybdenum, gold, silver, germanium and indium, chemicals, and fertilizers. In addition, it holds interest in oil sands projects in the Athabasca region of Alberta; and owns or has interests in 13 mines in Canada, the United States, Chile, and Peru, in addition to operates a metallurgical complex.
United Therapeutics Corporation (NASDAQ:UTHR)’s shares dropped -1.79% to $175.43.
United Therapeutics Corporation (UTHR) declared receipt of a Paragraph IV Certification Notice Letter from Watson Laboratories, Inc. (Watson) advising that Watson has presented an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting approval to market a generic version of Tyvaso® (treprostinil) Inhalation Solution.
In the Notice Letter, Watson states that it intends to market a generic version of Tyvaso® before the expiration of U.S. Patent No. 6,521,212, which expires in November 2018; U.S. Patent No. 6,756,033, which expires in November 2018; and U.S. Patent No. 8,497,393, which expires in December 2028. Watson’s Notice Letter states that the ANDA contains a Paragraph IV Certification alleging that these patents are not valid, not enforceable and/or will not be infringed by the commercial manufacture, use or sale of the projected product described in Watson ANDA submission.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases.
At the end of Friday’s trade, Burlington Stores Inc (NYSE:BURL)‘s shares surged 0.08% to $52.90.
Burlington Stores, Inc. (BURL), a nationally recognized off-price retailer of high-quality, branded apparel at everyday low prices, recently declared its results for the first quarter ended May 2, 2015.
Tom Kingsbury, Chairman and Chief Executive Officer stated, “We are happy with our 64% enhance in adjusted EPS which was driven by a robust gross margin expansion. While our comp sales were positive for the ninth successive quarter, we were negatively influenced by the timing of IRS tax refunds, lower markdown sales due to significantly less markdown inventory, raised store closures due to weather, and receipt flow issues in three key Easter businesses. With that said, I am optimistic about our business as comparable store sales have accelerated and we are in a great inventory position to take advantage of the many opportunities we see in the market place.”
First Quarter Fiscal 2015 Operating Results (for the 13 week period ended May 2, 2015 contrast with the 13 week period ended May 3, 2014):
- Comparable store sales raised 0.8% which follows a comparable store sales enhance of 2.7% in the first quarter of last year.
- Net sales raised 4.9%, or $54.8 million to $1,183.1 million. This enhance comprises the 0.8% enhance in comparable store sales, as well as an enhance of $49.2 million from new and non-comparable stores.
- Gross margin expanded by 160 basis points to 39.7% from 38.1% last year, primarily due to a reduction in markdowns. This more than offset an approximate 80 basis point enhance in product sourcing costs that are comprised of in selling and administrative expenses.
- SG&A, less product sourcing costs and advisory fees, as a percentage of net sales was 27.3% vs. 26.9% in the first quarter of last year. The enhance was due to a deleveraging of occupancy and marketing costs and enhances in severance and stock based compensation expense.
Burlington Stores, Inc. operates as a retailer of branded apparel products in the United States. The company offers fashion-focused merchandise, counting women’s ready-to-wear apparel, menswear, youth apparel, baby products, footwear, accessories, home décor and gifts, and coats. As of January 31, 2015, it operated 542 stores, counting an Internet store in 44 states and Puerto Rico. The company was founded in 1972 and is headquartered in Burlington, New Jersey.
Ventas, Inc . (NYSE:VTR), ended its Friday’s trading session with 1.57% gain, and closed at $62.79.
Ventas, Inc. (VTR) declared that it will issue its second quarter 2015 earnings release prior to the opening of trading on the New York Stock Exchange on Friday, July 24, 2015. A conference call to talk about those earnings will be held the same day at 10:00 a.m. Eastern Time (9:00 a.m. Central Time).
Ventas, Inc. is a publicly owned real estate investment trust. The firm engages in investment, administration, financing, and leasing of properties in the healthcare industry. It invests in the real estate markets of the United States and Canada. The firm primarily invests in healthcare-related facilities counting hospitals, skilled nursing facilities, senior housing facilities, medical office buildings, and other healthcare related facilities. Ventas, Inc. was founded in 1983 and is based in Chicago, Illinois with additional offices in Irvine, California; Louisville, Kentucky; Charlotte, North Carolina; and Dallas, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
